Trending...
- Tampa-Based Digital Marketing Agency Launches New Website to Help Local Businesses Grow Online - 114
- California: Governor Newsom announces new tax credits that will generate $2.1 billion investment in world's 4th largest economy
- New PSA Campaign to Address Black Maternal and Infant Mortality in Los Angeles County
Milestone Positions Company for Broader Clinical Adoption and Strategic Growth
IRVINE, Calif. - Californer -- VESICA HEALTH, INC., a pioneering diagnostics company transforming bladder cancer detection and hematuria management, proudly announces that its Irvine-based laboratory has earned accreditation by the College of American Pathologists (CAP). This achievement underscores Vesica Health's dedication to advancing early detection of bladder cancer, ensuring the highest standards of laboratory excellence, and improving outcomes for patients and healthcare providers alike.
"Securing CAP Accreditation is the culmination of an exceptional year of growth and innovation at Vesica Health," said Christopher Thibodeau, CEO of Vesica Health. "This milestone reflects our team's commitment to providing physicians and patients with the most reliable and advanced diagnostic solutions."
The CAP Accreditation is awarded after a comprehensive evaluation of laboratory processes, personnel qualifications, equipment, and quality management systems, ensuring compliance with the highest industry standards. This milestone underscores Vesica Health's dedication to precision diagnostics and its commitment to delivering reliable, high-quality results to healthcare providers and their patients.
Building on its California State Department of Health Clinical Laboratory License and CLIA Certification, Vesica Health's CAP Accreditation underscores a transformative year for the company. In 2024, Vesica successfully launched its flagship product, AssureMDx, on May 3, providing a critically needed non-invasive diagnostic tool for early bladder cancer detection. The company also established state-of-the-art laboratory operations in Irvine, CA, and forged key research collaborations with academic and clinical partners to develop next-generation diagnostics integrating advanced biomarkers and multi-omics technologies. These achievements reflect Vesica Health's commitment to precision diagnostics, regulatory excellence, and improving patient outcomes, positioning the company as a leader in the field.
More on The Californer
About AssureMDx™
AssureMDx is a proprietary, non-invasive urine-based DNA test addressing critical gaps in hematuria evaluation and early bladder cancer detection. With its successful launch on May 3, 2024, AssureMDx addresses critical gaps in bladder cancer detection through its industry-leading accuracy. Hematuria impacts 17 million U.S. adults annually, yet only 12% receive urological evaluation, leading to 20,000 missed bladder cancer diagnoses each year. Backed by 22 peer-reviewed studies involving over 6,000 patients, AssureMDx delivers industry-leading accuracy with a 0.96 AUC, 99% Negative Predictive Value (NPV), and 96% Sensitivity for the presence of bladder cancer. Traditional methods like cytology and cystoscopy suffer from limited sensitivity, while overuse of CT scans increases radiation exposure and the risk of secondary cancers. AssureMDx provides a precise solution, enabling timely urology referrals for high-risk patients and sparing low-risk patients from unnecessary invasive procedures and CT scans. Additionally, the test supports non-invasive monitoring for cancer recurrence, improving long-term outcomes. By reducing unnecessary procedures and improving healthcare efficiency, AssureMDx not only enhances patient outcomes but also delivers significant cost savings to healthcare systems. This innovative diagnostic tool exemplifies Vesica Health's mission to transform bladder cancer care through early detection, precision diagnostics, and improved patient outcomes.
About Vesica Health, Inc.
Vesica Health is a pioneering diagnostics company at the forefront of transforming bladder cancer detection and hematuria management. Positioned as a growth-stage company, Vesica has achieved significant milestones, including securing CAP Accreditation, a California State Department of Health Clinical Laboratory License, and CLIA certification for its Irvine-based laboratory. Building on over 20 years of advanced multi-omics research, Vesica launched its flagship product, AssureMDx, a clinically validated non-invasive diagnostic test with 96% sensitivity for the presence of disease, offering unparalleled precision for early bladder cancer detection and recurrence monitoring. With a strong operational foundation, Vesica Health is scaling its laboratory operations, expanding clinical adoption of AssureMDx, and pursuing partnerships to extend market reach. Looking ahead, the company is focused on driving commercialization, advancing its R&D pipeline, and exploring global expansion to address the unmet needs of millions of hematuria patients worldwide. Vesica Health represents a compelling investment opportunity in cutting-edge diagnostics with the potential to significantly impact patient care and healthcare systems. For more information, visit www.vesicahealth.com.
More on The Californer
About the College of American Pathologists
The College of American Pathologists is a globally recognized leader in laboratory quality assurance and accreditation. CAP accreditation is regarded as the gold standard for laboratory excellence, representing a commitment to quality, accuracy, and patient safety.
For investment and partnership inquiries, or to learn more about AssureMDx, please contact Vesica Health Corporate Communications at: public.relations@vesicahealth.com
"Securing CAP Accreditation is the culmination of an exceptional year of growth and innovation at Vesica Health," said Christopher Thibodeau, CEO of Vesica Health. "This milestone reflects our team's commitment to providing physicians and patients with the most reliable and advanced diagnostic solutions."
The CAP Accreditation is awarded after a comprehensive evaluation of laboratory processes, personnel qualifications, equipment, and quality management systems, ensuring compliance with the highest industry standards. This milestone underscores Vesica Health's dedication to precision diagnostics and its commitment to delivering reliable, high-quality results to healthcare providers and their patients.
Building on its California State Department of Health Clinical Laboratory License and CLIA Certification, Vesica Health's CAP Accreditation underscores a transformative year for the company. In 2024, Vesica successfully launched its flagship product, AssureMDx, on May 3, providing a critically needed non-invasive diagnostic tool for early bladder cancer detection. The company also established state-of-the-art laboratory operations in Irvine, CA, and forged key research collaborations with academic and clinical partners to develop next-generation diagnostics integrating advanced biomarkers and multi-omics technologies. These achievements reflect Vesica Health's commitment to precision diagnostics, regulatory excellence, and improving patient outcomes, positioning the company as a leader in the field.
More on The Californer
- Terra Divine Skincare Earns Coveted Spot on Organically Becca's Clean Brand Master List
- NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
- Emmetra Partners with Renesas to Advance Agentic AI-Powered Imaging Solutions
- Gravity to Bring 5-Minute EV Charging to 8 Sites Across Greater LA
- California: Governor Newsom issues statement on Pope Leo XIV, the first American Pope
About AssureMDx™
AssureMDx is a proprietary, non-invasive urine-based DNA test addressing critical gaps in hematuria evaluation and early bladder cancer detection. With its successful launch on May 3, 2024, AssureMDx addresses critical gaps in bladder cancer detection through its industry-leading accuracy. Hematuria impacts 17 million U.S. adults annually, yet only 12% receive urological evaluation, leading to 20,000 missed bladder cancer diagnoses each year. Backed by 22 peer-reviewed studies involving over 6,000 patients, AssureMDx delivers industry-leading accuracy with a 0.96 AUC, 99% Negative Predictive Value (NPV), and 96% Sensitivity for the presence of bladder cancer. Traditional methods like cytology and cystoscopy suffer from limited sensitivity, while overuse of CT scans increases radiation exposure and the risk of secondary cancers. AssureMDx provides a precise solution, enabling timely urology referrals for high-risk patients and sparing low-risk patients from unnecessary invasive procedures and CT scans. Additionally, the test supports non-invasive monitoring for cancer recurrence, improving long-term outcomes. By reducing unnecessary procedures and improving healthcare efficiency, AssureMDx not only enhances patient outcomes but also delivers significant cost savings to healthcare systems. This innovative diagnostic tool exemplifies Vesica Health's mission to transform bladder cancer care through early detection, precision diagnostics, and improved patient outcomes.
About Vesica Health, Inc.
Vesica Health is a pioneering diagnostics company at the forefront of transforming bladder cancer detection and hematuria management. Positioned as a growth-stage company, Vesica has achieved significant milestones, including securing CAP Accreditation, a California State Department of Health Clinical Laboratory License, and CLIA certification for its Irvine-based laboratory. Building on over 20 years of advanced multi-omics research, Vesica launched its flagship product, AssureMDx, a clinically validated non-invasive diagnostic test with 96% sensitivity for the presence of disease, offering unparalleled precision for early bladder cancer detection and recurrence monitoring. With a strong operational foundation, Vesica Health is scaling its laboratory operations, expanding clinical adoption of AssureMDx, and pursuing partnerships to extend market reach. Looking ahead, the company is focused on driving commercialization, advancing its R&D pipeline, and exploring global expansion to address the unmet needs of millions of hematuria patients worldwide. Vesica Health represents a compelling investment opportunity in cutting-edge diagnostics with the potential to significantly impact patient care and healthcare systems. For more information, visit www.vesicahealth.com.
More on The Californer
- New poll shows high rates of employee burnout amid concerns over politics and personal finances
- Tessellations Appoints Luthern Williams as Head of School
- Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
- Psychological Thriller "Killing Off Connor" To Open 34th IFS Film Fest After 12-years In Post
- Harvest Properties Acquires Two San Francisco Bay Area Self Storage Facilities for $44.2 Million
About the College of American Pathologists
The College of American Pathologists is a globally recognized leader in laboratory quality assurance and accreditation. CAP accreditation is regarded as the gold standard for laboratory excellence, representing a commitment to quality, accuracy, and patient safety.
For investment and partnership inquiries, or to learn more about AssureMDx, please contact Vesica Health Corporate Communications at: public.relations@vesicahealth.com
Source: Vesica Health
0 Comments
Latest on The Californer
- Long Beach to Commemorate its Naval History with Commemorative Community Event
- Long Beach: City Celebrates Inaugural National Home Improvement Month: Love Where You Live
- California sues Trump administration for illegally withholding billions in bipartisan infrastructure funds: 'Another Trump gift to China'
- Tale of two trains: California high-speed rail leaves Texas in the dust
- California: State invests nearly $33 billion in cap-and-trade dollars to make communities cleaner and healthier
- Where AI Falls Short, Real Connections Rise—Media Outreach with Heart
- Cybersecurity is Protecting Your Personal Information and Your Portfolio
- EY US unveils Puneet Nanda of GuruNanda as an Entrepreneur Of The Year® 2025 Award Finalist
- California: Governor Newsom proclaims Children's Mental Health Awareness Week 2025
- VC Mastermind Launches: A Private Global Network and Podcast for Top-Tier Venture Capital Leaders
- L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
- Actor and Writer Ernie Rivera Launches Groundbreaking Indie Superhero Thriller, Citadel Lost, with Full Campaign and Industry Buzz
- Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
- Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
- ViroMissile Unveils IDOV™ Platform: A Potential One-Shot Cure for Cancer
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
- SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
- New National Nonprofit Launches to Capture Firsthand Accounts of Adoption Stories
- The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices